anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study aimed to investigate the feasibility of using ground soybean hulls and white oat grains to finish steers reared exclusively on concentrated feed. We used 33 steers, predominantly of Charolais or Nellore breeds, and randomly assigned the animals to the treatments, blocking them according to genetic predominance. The diets were isonitrogenous, and the treatments consisted of soybean hulls, white oats, and mix these in equal parts, supplemented with calcitic limestone and a protein nucleus. The study measured variables related to the dry matter intake (DMI) and bromatological fractions of diets, as well as performance of steers. No significant differences were observed between treatments in terms of DMI during the experimental period. Although DMI intake was similar across treatments, steers receiving the mixed diet exhibited significantly higher weight gain than those on the soybean hull diet (1.300 vs. 0.972 kg day-1). However, both these treatments showed comparable results to the white oat grain diet (1.203 kg day-1), achieving a similar final weight (387.22 kg). Implementing 100% concentrate diets is technically feasible for steers fed with white oat grain and the mixture of soybean hull and white oat grain, which also demonstrated superior performance compared to the soybean hull treatment.
PURPOSE: A composition containing Melia azedarach L. var. japonica Makino extract for hair and scalp care is provided to suppress conversion of testosterone into dehydrotestosterone. CONSTITUTION: A composition for hair and scalp care contains 0.5-20.0 wt% of plant extract isolated from Melia azedarach L. var. japonica Makino fruits. The composition is manufactured in the form of a shampoo, rinse, hair gel, hair mousse, hair spray, hair tonic, or hair pack. The solvent is ethanol, propylene glycol, butylene glycol, polyol, or purified water.
OBJECTIVE: In this study, we aimed to perform a network meta-analysis (NMA) to investigate the effects of different testosterone replacement therapy (TRT) administration routes on lower urinary tract symptoms (LUTS) in aging men with late-onset hypogonadism (LOH).
METHODS: A systematic search of PubMed, Embase, The Cochrane Library, CNKI, WanFang Data, and VIP was conducted to identify randomized controlled trials (RCTs) reporting data on International Prostate Symptom Score (IPSS), prostate-specific antigen (PSA) level, or prostate volume. NMA was performed, and subgroup analysis was conducted to assess the impact of TRT duration on outcomes.
RESULTS: A total of 21 RCTs involving 2453 participants were included. For pairwise meta-analysis, p values for TRT delivered by transdermal, intramuscular, and oral routes were as follows: IPSS: 0.93, 0.20, and 0.76; PSA level: 0.20, 0.27, and 0.98; prostate volume: 0.18, 0.04, and 0.16. There were no significant differences in IPSS, PSA level, or prostate volume between TRT routes. In subgroup analysis, long-term intramuscular TRT significantly decreased IPSS (p = 0.03), short-term transdermal TRT increased PSA levels (p < 0.001), and short-term intramuscular TRT increased the prostate volume (p = 0.04). Other forms of TRT showed no significant change in IPSS, PSA level, and prostate volume compared with the placebo. Indirect comparison of the three administration routes demonstrated no significant differences in IPSS, PSA level, and prostate volume. Nevertheless, surface under the cumulative ranking curve analysis indicated that intramuscular TRT had an 83% probability of being the best method for decreasing IPSS.
CONCLUSIONS: The results demonstrate that TRT does not worsen LUTS regardless of the administration route. Intramuscular TRT may be the preferred treatment for aging men with LOH and LUTS. Intramuscular TRT may be the preferred treatment for men with LOH and LUTS. Further research is warranted to validate these findings and optimize TRT management strategies.
The present invention relates to a device for measuring, recording, and acting in response to changes in air pressures encountered through the lumen of a connected needle. The device signals when it has been powered and signals when the device recognizes both pressures and pressure change rates indicative of synovial cavity joint penetration, such as knee joint penetration. Synovial cavity pressures detected and acted upon may either be supra- (positive) or sub-atmospheric (negative). Internal light emitting diodes and a laptop connected display are demonstrated as signaling and communication mechanisms. Methods for delivering medicaments into human and animal intra-articular cavities or joints such as synovial cavities are provided. Furthermore, methods for facilitating the diagnoses of joint effusion also are provided.
PURPOSE:The titled composition, obtained by incorporating methyl cellulose with hydroxypropyl methyl cellulose which is a coating base material, and having reduced slimy feeling in the mouth in administration with the retained advantage of the coating base material and improved feeling of administration. CONSTITUTION:A coating composition for a solid pharmaceutical obtained by incorporating methyl cellulose (hereinafter abbreviated to MC) with hydroxypropyl methyl cellulose (hereinafter abbreviated to HPMC). The HPMC has many advantages such as easy coating operation and good disintegrating property, etc. but a disadvantage in that a slimy feeling is caused in administration of a pharmaceutical coated with the HPMC. The incorporation of the MC with the HPMC is found to improve the disadvantage of causing the slimy feeling without reducing the advantages of the HPMC. In the process, the mixing weight ratio between the HPMC and MC is (8:2)-(2:8), preferably (7:3)-(3:7).
In acute coronary artery disease, pre-clinical studies have indicated that, during a continuous infusion of intravenous perfluorocarbon containing microbubbles, the ultrasonic power delivered from a diagnostic ultrasound transducer is capable of restoring microcirculatory flow and improving epicardial recanalization rates obtained by conventional therapy, a process known by Sonothrombolysis. Since both diagnostic ultrasound and intravenous infusions of microbubbles are a Class I indication to assess regional and global left ventricular function and risk area in patients with ST segment elevation myocardial infarction (STEMI). The investigators propose to examine the effectiveness of microvascular sonothrombolysis.

A total of 100 patients with acute STEMI will be randomized to receive diagnostic ultrasound guided high mechanical index (MI) impulses in different approaches applied within and outside the risk area during a continuous infusion of intravenous 3% Definity® or placebo. The different ultrasound regimens are: Group I - a custom designed high mechanical index (MI) impulses at 4-20 usec and \>1.0 MI designed for the 1.7 MHz S5-1 transducer; Group II - repeated diagnostic high MI impulses (all \<2 usec pulse duration; MI=1.0 whenever very low MI perfusion imaging detected microbubbles within the microvasculature; Group III (control), where a few limited diagnostic high MI impulses (n\<5 per patient) will be applied to assess myocadial perfusion before and after percutaneous coronary intervention (PCI). All patients will receive the conventional PCI approach, including 325 milligrams Aspirin, 600 milligrams Clopidogrel, and heparin bolus (5000 units), followed by primary PCI using glycoprotein 2b/3a inhibitors as anti-thrombotic agents using established protocols. Besides angiographic recanalization rates at the time of presentation to the catheterization laboratory, the patients will have a magnetic resonance exam performed at 72-96 hours post infarcton to quantify the myocardial salvagability index. Quantitative assessments of ejection fraction will be made at this time as well.Overall survival (OS), defined as the time from the start of treatment to death from any cause, will be evaluated.Comparisons between the three groups will be made on door to dilation times, survival, angiographic recanalization rates (ARR) at initial angiography, and reduction in infarct size determined by the salvagability index (SI) at magnetic resonance imaging 72-96 hours post STEMI. Left ventricular function and perfusion parameters by echocardiography will also be evaluated during, at 72-96 hours and at 6 months in all subjects.
The project consists of a screening and baseline monitoring period of 1-2 weeks, and a treatment period of 1 week, followed by a 3-month follow-up period. Approximately 108 participants will be randomized in a blinded manner to one of three arms in a 1:1:1 fashion (everolimus 1h : everolimus 8-9h : Placebo). After screening, participants will have the first video-EEG monitoring for up to 24 hours to assess baseline levels, followed by 1 week of treatment, the second video-EEG monitoring, and a 3-month post treatment follow-up period. During the treatment period, participants will be given everolimus or placebo directed to seizure events. In the "everolimus 1h" group, everolimus will be administrated immediately after seizure events (within 1 hour); while in the "everolimus 8-9h" group, everolimus administration will be delayed (at 8-9 hours after seizure events). We conduct this study to assess the efficacy of everolimus in adult refractory epilepsy patients under an administration strategy in a limited time window immediately after seizure events.
PROBLEM TO BE SOLVED: To obtain a peptide compound effective for remarkably suppressing the progress of systemic lupus erythematosus without causing grave side action and capable of suppressing the renal damage caused by the progress of systemic lupus erythematosus. SOLUTION: A peptiae compound of formula I (X1 and X2 are each an amino acid residue of L or D-tyrosine or arginine; (n) is 2, 3 or 4; R is a group capable of forming a peptide dimer, trimer or tetramer) is used in the present invention. Examples of the compound of formula I are compounds of formulas II-IV. The drug composition to be used for the treatment of systemic lupus erythematosus contains the active amount of the compound of formula I and at least one pharmacologically permissible inert component. The amount of the compound of formula I in the composition is preferably selected to attain an administration level of 2-50 mg/kg/day. A drug composition effective for the treatment of systemic lupus erythematosus and free from grave side action is expectable by the use of the compound.
OBJECTIVE: Unplanned returns to the operating room (RORs) constitute an important quality metric in surgical practice. In this study, the authors present a methodology to compare a department's unplanned ROR rates with national benchmarks in the context of large-scale quality of care surveillance.
METHODS: The authors identified unplanned RORs within 30 days from the initial surgery at their institution during the period 2014-2018 using an institutional documentation platform that facilitates the collection of reoperation information by providers in the clinical setting. They divided the procedures into 28 groups by Current Procedural Terminology and International Classification of Diseases, 9th and 10th Revision codes. They estimated national benchmarks of unplanned RORs for these procedure groups via querying the American College of Surgeons (ACS) National Surgical Quality Improvement Program (NSQIP) registry during the period 2014-2018. Finally, they numerically assessed the unplanned ROR rates at their institution compared with those calculated from the ACS NSQIP registry.
RESULTS: Using the above methodology, the authors were able to classify 12,575 of the cases performed in their department during the period of interest, including 6037 (48%) cranial cases and 6538 (52%) spinal or peripheral nerve cases. Among those, 161 (1.3%) presented with complications that required an unplanned ROR within 30 days from the initial surgery. The respective cumulative unplanned ROR rate in the ACS NSQIP registry during the same timeframe was 3.6%. Among 15 categories of cranial procedures, the cumulative unplanned ROR rate was 1.3% in the authors' department and 5.6% in the ACS NSQIP registry. Among 13 categories of spinal and peripheral nerve procedures, the cumulative unplanned ROR rate was 1.3% in the authors' department and 2.8% in the ACS NSQIP registry. Unplanned ROR rates at the authors' institution were lower than the national average for each of the 28 procedure groups of interest. Yearly analysis of institutional ROR rates for the five most commonly performed procedures showed lower reoperation rates compared with the national benchmarks.
CONCLUSIONS: Using an institutional documentation tool and a widely available national database, the authors developed a reproducible and standardized method of comparing their department's outcomes with national benchmarks per procedure subgroup. This methodology accommodates longitudinal quality surveillance across the different subspecialties in a neurosurgical department and may illuminate potential shortcomings of care delivery in the future.
BACKGROUND: Chronic limb-threatening ischemia (CLTI) in patients with end-stage renal disease (ESRD) poses significant challenges in clinical management due to its unique pathology and poor treatment outcomes. This review calls for a tailored classification and risk assessment for these patients to guide better revascularization choices with early minor amputation as a first-line strategy in advanced stages.
METHODS: This review consolidates key findings from recent literature on CLTI in ESRD, focusing on disease mechanisms, treatment options, and patient outcomes. It evaluates the literature to clarify the decision-making process for managing CLTI in ESRD.
RESULTS: CLTI in ESRD patients often results in worse clinical outcomes, such as nonhealing wounds, increased limb loss, and higher mortality rates. While the literature reveals ongoing debates regarding the optimal revascularization method, recent retrospective studies and meta-analyses suggest potential benefits of endovascular treatment (EVT) over open bypass surgery (OB) in reducing mortality and wound complications, with comparable amputation-free survival rates.
CONCLUSIONS: The selection of revascularization methods in ESRD patients with CLTI is complex, necessitating individualized strategies. The importance of early detection and timely intervention is critical to decelerate disease progression and improve revascularization outcomes. There is a shift in these treatment strategies toward less invasive endovascular procedures, acknowledging the limitations these patients face with open revascularization surgeries. Considering early minor amputations after revascularization could prevent worse consequences, reflecting a shift in the approach to managing CLTI in ESRD patients.
Despite large-scale, nationwide efforts to better address suicidal behavior (defined as thoughts and behavior) in high-risk Veterans with major depressive disorder (MDD), the development of interventions that target some of the key risk factors associated with suicide in Veterans with MDD remains limited. That is, while much intervention research continues to investigate treatments like cognitive behavioral therapy (CBT) that target behavioral patterns, emotion processing problems, and cognitive styles associated with suicide risk in MDD, deficits in the neurocognitive substrates that underlie these CBT targets remain under-addressed. Cognitive remediation (CR) and rehabilitation have long been a primary treatment for patients with other psychiatric illnesses, like schizophrenia, for improving cognitive functioning and facilitating transfer of cognitive skills to every-day functioning. However, scant work has examined CR that addresses the neurocognitive deficits underlying suicidal behavior in individuals with MDD. Empirical work has identified key executive functioning (EF) deficits that may be specific to MDD patients with suicidal behavior, and meta-analytic work indicates that CR has moderate effect sizes on cognitive functioning, depression, and daily functioning in MDD. Thus, the field is in dire need of work that examines CR as a recovery-oriented treatment approach for MDD patients at risk for suicide.

The proposed study aims to collect pilot data to test the feasibility and acceptability of adjunctive neuroplasticity-based CR on key treatment targets delivered via telehealth during this time of COVID-19 in a sample of 36 Veterans with MDD and a history of suicide attempt(s). Specifically, it will test the effects of an adjunctive evidence-based cognitive remediation (CR) therapy (adjunctive to treatment as usual) augmented with manualized "Bridging" sessions on transfer and practice of cognitive control and decision-making/problem-solving strategies for real-world situations and problems, including those that trigger suicidal thoughts. The investigators propose to administer the Neuropsychological Educational Approach to Cognitive Remediation (NEAR, termed CR plus "Bridging" session, CR+Bridging) to a total of 36 Veterans with MDD and a history of suicide attempt(s). The intervention will be delivered in 20 90-minute sessions (2x/week for 10 weeks). Pre-treatment assessments of neurocognitive, clinical, social, and real-world functioning will be conducted, including measures that examine the impact of COVID-19 and its accompanying "social-distancing" restrictions. Posttreatment assessments of the same targets will be conducted to determine clinical response to and feasibility of this therapeutic intervention immediately following conclusion of the intervention (Week 10) and at a follow-up assessment (Week 20). This application is novel in that it constitutes the first implementation of this intervention in Veterans with MDD and suicidal behavior. Consistent with RR\&D's SPiRE mechanism, this study is high risk, but it has high potential impact and promise to help improve quality of life for Veterans at high risk for suicide.
The current practice to avoid incisional hernia, one of the most frequent complications following abdominal surgery, is to minimize core muscle activity in the postoperative phase. Therefore the patients are instructed not to bear or lift weights and to limit physical activities in the first 8-12 weeks after surgery. However, there is no evidence to support the association of core muscle activity and increased incidence of incisional hernia. On the contrary, it is likely that reduced physical activity and deconditioning of the core muscles is associated with muscle catabolism, which may lead to physical deconditioning, chronic postsurgical pain (CPSP), and sarcopenia. CPSP is primarily a major burden in terms of reduced quality of life and resource utilization whereas sarcopenia in addition is increasingly recognized as an important independent risk factor for numerous adverse clinical outcomes and mortality.

The investigators will conduct a prospective multicentric randomized clinical trial to compare standard of care to core muscle exercises targeting the abdominal muscles immediately postsurgery. The principle hypothesis is that neither specific exercises of core muscles before and after surgery nor physical restriction alter the incidence of incisional hernias. Secondly the impact of postoperative rehabilitation on CPSP and sarcopenia will be assessed. The patients will be divided into two study arms, one receiving standard of care and the other receiving the intervention. The intervention consists of four specific core muscle exercises to perform daily during the first two months after surgery. Follow-up will be at two, twelve and twenty-four months with clinical examination and ultrasound to detect incisional hernias, assessment chronic postsurgical pain and its treatment and evaluation of muscle mass on CT scans.
The invention relates to a traditional Chinese medicine preparation for treating Parkinson's disease, which is prepared from the following raw materials: prepared rhizome of rehmannia, Chinese angelica, white peony root, asarum, gastrodia tuber, clematis root, mistletoe, gentian, rhubarb, prepared pinellia tuber and other 17 kinds of Chinese medicinal materials and prepared into bolus or decoction for oral administration. Parkinson's disease belongs to the field of paralysis agitans of traditional Chinese medicine, and is manifested by the main clinical symptoms of head shaking, involuntary tremor of limbs, muscle stiffness, gait and posture disorder and the like. The traditional Chinese medicine considers that: "all the tendons and vessels can not be restricted, which belongs to the wind condition". It is considered that the deficiency of yin and blood is the main cause and the wind-fire cannot be stopped, so it is difficult to treat any syndrome. Western medicine considers that the disease is a common nervous system disease, the disease is caused by the decrease of dopamine content in the substantia nigra, a black nucleus in the midbrain, and the imbalance of acetylcholine function, and the currently applied treatment means can only improve symptoms, cannot prevent the development of the disease, and cannot cure the disease. The invention has the functions of tonifying liver and kidney, calming liver wind, benefiting qi and nourishing blood, reducing phlegm and removing blood stasis and removing dampness, so the clinical treatment effect is good, the cure rate can reach more than 95 percent, and the effective rate is 100 percent.
The invention discloses an antigenic peptide for the dimerization of an epidermal growth factor receptor, and relates to the field of the preparation of therapeutic polypeptide vaccines and antibody medicaments. An amino acid sequence of the antigenic peptide is SEQ ID NO: 1 or SEQ ID NO: 2 or a polypeptide which is subjected to the substitution and/or deletion and/or addition of one or more of amino acid residues and has the antigenic activity of the dimerization of the epidermal growth factor receptor. The invention also discloses a fusion antigenic peptide for the dimerization of the epidermal growth factor receptor, and the fusion antigenic peptide is a fusion peptide formed by the antigenic peptide and measles virus of fusion protein (MVF) serving as a general T cell epitope peptide. The antigenic peptide or the fusion antigenic peptide is mainly used for preparing the therapeutic vaccines. The preparation cost of the vaccines is far lower than that of various humanized or human antibodies, and large-dose and long-term repeat administration of the humanized or human antibodies is avoided, so the using cost is low, and the toxic and side effects are small. Compared with a chemical synthesis method, the recombination deoxyribonucleic acid (DNA) technology for preparing the antigenic peptide has the advantages that: the cost is low, and industrial amplification and quality control are easy.
Participants in the conventional rehabilitation group will be given a treatment protocol consisting of stretching, strengthening exercises and joint mobilization techniques for a total of 4 weeks, 3 days a week for 45 minutes. Assessments will be applied in the baseline and at the end of 4 weeks.